样式: 排序: IF: - GO 导出 标记为已读
-
Enteral nutrition compared with corticosteroids in children with Crohn's disease: A long‐term nationwide study from the epi‐IIRN Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-05-14 Luba Plotkin, Rachel Buchuk, Rona Lujan, Gili Focht, Shira Greenfeld, Revital Kariv, Yiska Loewenberg Weisband, Natan Lederman, Eran Matz, Iris Dotan, Ram Reifen, Dan Turner
-
Letter: Intestinal permeability accounting for ongoing gastrointestinal symptoms following endoscopic remission in IBD Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-05-10 Rupert W. Leong, Vipul Jairath, Christopher Ma
LINKED CONTENTThis article is linked to Aliu et al papers. To view these articles, visit https://doi.org/10.1111/apt.17988 and https://doi.org/10.1111/apt.18031.
-
Letter: Intestinal permeability accounting for ongoing gastrointestinal symptoms following endoscopic remission in IBD—Authors' reply Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-05-10 Arta Aliu, Daan H. C. A. Bosch, Daniel Keszthelyi, Ashkan Rezazadeh Ardabili, Jean‐Frederic Colombel, Rachel Sawyer, Hans Törnblom, Ailsa Hart, Daisy M. A. E. Jonkers, Marieke J. Pierik, Zlatan Mujagic
LINKED CONTENTThis article is linked to Aliu et al papers. To view these articles, visit https://doi.org/10.1111/apt.17988 and https://doi.org/10.1111/apt.18027.
-
Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real-world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-05-08 Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Hiroki Nishikawa, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Yuichi Koshiyama, Hidenori Toyoda, Chikara Ogawa, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Hideko Ohama, Fujimasa Tada, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui
-
Editorial: High qHBsAg—Is it a good or bad signal? Authors' reply Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-05-08 Hsin‐Che Lin, Wen‐Juei Jeng, Hwai‐I Yang
LINKED CONTENTThis article is linked to Lin et al papers. To view these articles, visit https://doi.org/10.1111/apt.17915 and https://doi.org/10.1111/apt.17965.
-
Letter: Potential confounders might exaggerate the risk of rheumatoid arthritis in patients with microscopic colitis—Authors' reply Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-05-08 David Bergman, Jonas F. Ludvigsson
LINKED CONTENTThis article is linked to Bergman et al papers. To view these articles, visit https://doi.org/10.1111/apt.17708 and https://doi.org/10.1111/apt.18010.
-
Letter: Potential confounders might exaggerate the risk of rheumatoid arthritis in patients with microscopic colitis Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-05-08 Fang Yan, Pengshuang Shi, Shimin Wu, Jie Yang, Dejun Cui
LINKED CONTENTThis article is linked to Bergman et al. papers. To view these articles, visit https://doi.org/10.1111/apt.17708 and https://doi.org/10.1111/apt.18018.
-
-
Editorial: Hepatitis C virus eradication improves skeletal muscle mass Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-05-07 Catherine Jia Lin Tian, Jing Hieng Ngu
LINKED CONTENTThis article is linked to Coelho et al papers. To view these articles, visit https://doi.org/10.1111/apt.17950 and https://doi.org/10.1111/apt.18005
-
Letter: Presence of progression or absence of response? Alternative trial designs for immunotherapy of advanced hepatocellular carcinoma. Authors' reply Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-05-07 Raphael Mohr, Frank Tacke, Christoph Roderburg
LINKED CONTENTThis article is linked to Jost‐Brinkmann et al papers. To view these articles, visit https://doi.org/10.1111/apt.17441 and https://doi.org/10.1111/apt.17985
-
Editorial: Hepatitis C virus eradication improves skeletal muscle mass—Authors' reply Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-05-07 Marta Paula Pereira Coelho, Thais Pontello de Vries, Aline Marcos Pires, Milena Pereira Parreira, Érika Ramos de Alvarenga, Rodrigo Dias Cambraia, Rodrigo Ribeiro dos Santos, Juliana Maria Trindade Bezerra, Enrico Antonio Colosimo, Gifone Aguiar Rocha, Luciana Diniz Silva
LINKED CONTENTThis article is linked to Coelho et al papers. To view these articles, visit https://doi.org/10.1111/apt.17950 and https://doi.org/10.1111/apt.17978
-
Editorial: Exploring the influence of diet on later‐onset ulcerative colitis—Are eggs and spicy foods the key factors in Asia? Authors' reply Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-05-07 Shuyao Song, Jun Lv, Liming Li, Yuanjie Pang
LINKED CONTENTThis article is linked to Song et al papers. To view these articles, visit https://doi.org/10.1111/apt.17963 and https://doi.org/10.1111/apt.17983
-
Letter: Boosting non‐invasive tests—Opportunities and challenges from resmetirom Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-05-06 Gong Feng, Calvin Q. Pan, Ming‐Hua Zheng
Editors, We read with great interest the recent article regarding resmetirom—a promising treatment option for metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis.1 In fact, another groundbreaking hallmark of resmetirom is that the US Food and Drug Administration (FDA) does not require a liver biopsy to determine a patient's eligibility for the medication.2 Consequently, non-invasive
-
Editorial: Mortality in immune‐mediated inflammatory diseases during early adulthood—Authors' reply Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-05-06 Mikkel Malham, Sabine Jansson, Helene Ingels, Marianne Hørby Jørgensen, Naja Hulvej Rod, Vibeke Wewer, Matthew P. Fox
We are grateful to Dr. Henderson for the kind words in his editorial1 and for accurately summarising our paper.2 As Dr. Henderson recognised, cancer was a leading cause of mortality in our nationwide cohort of patients diagnosed with paediatric-onset immune-mediated inflammatory disease (pIMID). This suggests that IMID affects the risk of cancer, which is well known in paediatric-onset inflammatory
-
Letter: The enigma of angiotensin receptor blocker‐associated enteropathy—Authors' reply Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-05-06 Annalisa Schiepatti, Stiliano Maimaris, Federico Biagi, David S. Sanders
We read with interest the letter by Mohamedrashed et al. highlighting the crucial homeostatic role of the renin–angiotensin system (RAS) for gut homeostasis, and its potential involvement as a key player in the pathogenesis of angiotensin II receptors blockers (ARBs)-associated enteropathy and other gastrointestinal disorders such as inflammatory bowel disease (IBD).1 A bidirectional interaction between
-
Editorial: Can dietary gluten restriction improve hepatic steatosis? Authors' reply Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-05-06 Angelo Armandi, Detlef Schuppan, Jörn M. Schattenberg
On behalf of all co-authors of our recently published paper,1 we thank Dr. Kranidioti and Dr. Deutsch for the analysis and insightful comments provided.2 The basis of the present and future management of metabolic dysfunction-associated steatotic liver disease (MASLD) are lifestyle interventions with or without potential pharmacological treatments.3 The MASLD covers a broad spectrum of liver phenotypes
-
The use of opioids nine months after surgery for Crohn's disease – a nationwide cohort study Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-05-02 Bente Mertz Nørgård, Caroline Thingholm Thorarinsson, Floor Dijkstra Zegers, Jens Kjeldsen, Rahul S. Dalal, Ken Lund, Torben Knudsen
-
Real‐life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-05-02 Juan Carlos Ruiz‐Cobo, Jordi Llaneras, Xavier Forns, Adolfo Gallego Moya, Isabel Conde Amiel, Ana Arencibia, Moises Diago, Javier García‐Samaniego, Jose Castellote, Susana Llerena, Elisa Rodríguez‐Seguel, Beatriz Mateos, Manuel Rodríguez, Jose Miguel Rosales Zabal, Inmaculada Fernández, Jose Luis Calleja, Rosa María Morillas, Silvia Montoliu, Raul J. Andrade, Ester Badia Aranda, Manuel Hernández‐Guerra
-
Review article: Evaluation and care of the critically ill patient with cirrhosis Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-05-02 Iva Kosuta, Madhumita Premkumar, K. Rajender Reddy
-
The deep abdominal ultrasound transducer (DAX) increases the success rate and diagnostic accuracy of shear wave elastography for liver fibrosis assessment in patients with obesity—A prospective biopsy‐controlled study Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-05-02 David J. M. Bauer, Larissa Nixdorf, Nina Dominik, Michael Schwarz, Benedikt S. Hofer, Lukas Hartl, Georg Semmler, Mathias Jachs, Benedikt Simbrunner, Julia Jedamzik, Behrang Mozayani, Lisa Gensthaler, Daniel Moritz Felsenreich, Michael Trauner, Felix Benedikt Langer, Mattias Mandorfer, Gerhard Prager, Thomas Reiberger
-
Updates in characteristics and survival rates of cirrhosis in a nationwide cohort of real‐world U.S. patients, 2003–2021 Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-05-02 Sally Tran, Biyao Zou, KeeSeok Lee, Leslie Kam, YeeHui Yeo, Linda Henry, Ramsey Cheung, Mindie H. Nguyen
-
Longitudinal outcomes of obeticholic acid therapy in ursodiol‐nonresponsive primary biliary cholangitis: Stratifying the impact of add‐on fibrates in real‐world practice Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-05-01 E. Gómez, J. L. Montero, E. Molina, L. García‐Buey, M. Casado, J. Fuentes, M. A. Simón, A. Díaz‐González, F. Jorquera, R. M. Morillas, J. Presa, M. Berenguer, M. I. Conde, A. Olveira, G. Macedo, I. Garrido, M. Hernández‐Guerra, I. Olivas, S. Rodríguez‐Tajes, M. Londoño, J. M. Sousa, J. Ampuero, E. Romero‐González, Sh. González‐Padilla, D. Escudero‐García, A. Carvalho, A. Santos, M. L. Gutiérrez, E
-
Recent steroid use and the relapse risk in ulcerative colitis patients with endoscopic healing Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-23 Tomohiro Fukuda, Hajime Yamazaki, Yusuke Miyatani, Tsunaki Sawada, Naoki Shibuya, Yuka Fukuo, Hiroki Kiyohara, Hiromu Morikubo, Keiichi Tominaga, Kazuki Kakimoto, Takayuki Imai, Katsuki Yaguchi, Shojiro Yamamoto, Katsuyoshi Ando, Nobuaki Nishimata, Takeo Yoshihara, Akira Andoh, Toshifumi Hibi, Katsuyoshi Matsuoka
-
Letter: Shorter duration of intravenous terlipressin for variceal bleeding in patients with cirrhosis—A promising find. Author's reply Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-23 Sagnik Biswas, Manas Vaishnav, Shalimar
This article is linked to Vaishnav et al papers. To view these articles, visit https://doi.org/10.1111/apt.17868 and https://doi.org/10.1111/apt.17976
-
Long‐term clinical outcomes in steatotic liver disease and incidence of liver‐related events, cardiovascular events and all‐cause mortality Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-26 Nobuharu Tamaki, Takefumi Kimura, Shun‐Ichi Wakabayashi, Takeji Umemura, Masayuki Kurosaki, Rohit Loomba, Namiki Izumi
-
Letter: Association of persistently high HBsAg levels during HBeAg-seropositive stage and hepatocellular carcinoma risk in chronic hepatitis B patients—Authors' reply Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-25 Hsin-Che Lin, Wen-Juei Jeng, Hwai-I Yang
This article is linked to Lin et al papers. To view these articles, visit https://doi.org/10.1111/apt.17915 and https://doi.org/10.1111/apt.17971
-
Dietary factors and patterns in relation to risk of later-onset ulcerative colitis in Chinese: A prospective study of 0.5 million people Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-23 Shuyao Song, Zhiyu Wu, Jun Lv, Canqing Yu, Dianjianyi Sun, Pei Pei, Lang Pan, Ling Yang, Yiping Chen, Huaidong Du, Lingli Chen, Dan Schmidt, Daniel Avery, Liping Duan, Junshi Chen, Zhengming Chen, Liming Li, Yuanjie Pang
-
Editorial: Sequencing rescue therapy for acute severe ulcerative colitis—Ready for revision? Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-23 L. A. A. P. Derikx, F. Hoentjen
LINKED CONTENTThis article is linked to García et al papers. To view these articles, visit https://doi.org/10.1111/apt.17938 and https://doi.org/10.1111/apt.17993
-
Editorial: Is it time to include oral vancomycin in therapeutic guidelines for primary sclerosing cholangitis‐associated inflammatory bowel disease? Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-23 Ayesha Shah, Gerald Holtmann
LINKED CONTENTThis article is linked to Ricciuto et al paper. To view this article, visit https://doi.org/10.1111/apt.17936
-
Editorial: Terlipressin and MDRO colonisation in cirrhosis—Is there a causal link? Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-23 Luciano Revelli, Melisa Dirchwolf
LINKED CONTENTThis article is linked to Mücke et al paper. To view this article, visit https://doi.org/10.1111/apt.17899
-
Meta-analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-23 Tsz Hong Yiu, Yanna Ko, Aviv Pudipeddi, Patrizia Natale, Rupert W. Leong
-
Editorial: Sequencing rescue therapy for acute severe ulcerative colitis—Ready for revision? Authors' reply Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-23 María José García, Javier P. Gisbert, María Chaparro
LINKED CONTENTThis article is linked to García et al papers. To view these articles, visit https://doi.org/10.1111/apt.17938 and https://doi.org/10.1111/apt.17973
-
Steatotic liver disease‐associated all‐cause/cause‐specific mortality in the United States Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-23 Donghee Kim, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed
-
Letter: Bif195 for aspirin‐induced gastric mucosal damage – More to do in further research. Authors' reply Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-23 Nina Løn, Sara Engel, Anders Damholt, Anja Wellejus, Filip K. Knop
LINKED CONTENTThis article is linked to Løn et al papers. To view these articles, visit https://doi.org/10.1111/apt.17817 and https://doi.org/10.1111/apt.17984
-
Letter: Bif195 for aspirin‐induced gastric mucosal damage—More to do in further research Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-23 Yuxin Wang, Wenwan Peng, Mingguo Dong
LINKED CONTENTThis article is linked to Løn et al papers. To view these articles, visit https://doi.org/10.1111/apt.17817 and https://doi.org/10.1111/apt.18002
-
Editorial: Adequate protein intake is more crucial than the profile of amino acids intake for sarcopenia prevention during the earlier stages of liver cirrhosis Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-23 Meropi D. Kontogianni
LINKED CONTENTThis article is linked to Hey et al paper. To view this article, visit https://doi.org/10.1111/apt.17917
-
Letter: Shorter duration of intravenous terlipressin for variceal bleeding in patients with cirrhosis—A promising find Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-23 Leya Nedumannil, Mustafa Mohamedrashed, Siddharth Sood, Diana Lewis
LINKED CONTENTThis article is linked to Vaishnav et al papers. To view these articles, visit https://doi.org/10.1111/apt.17868 and https://doi.org/10.1111/apt.17982
-
Hepatic inflammation and fibrosis are profiles related to mid‐term mortality in biopsy‐proven MASLD: A multicenter study in Japan Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-23 Tsubasa Tsutsumi, Takumi Kawaguchi, Hideki Fujii, Yoshihiro Kamada, Hirokazu Takahashi, Miwa Kawanaka, Yoshio Sumida, Michihiro Iwaki, Hideki Hayashi, Hidenori Toyoda, Satoshi Oeda, Hideyuki Hyogo, Asahiro Morishita, Kensuke Munekage, Kazuhito Kawata, Koji Sawada, Tatsuji Maeshiro, Hiroshi Tobita, Yuichi Yoshida, Masafumi Naito, Asuka Araki, Shingo Arakaki, Hidenao Noritake, Masafumi Ono, Tsutomu Masaki
-
Editorial: Crystalising the burden of steatotic liver disease—Authors' reply Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-23 Carolin V. Schneider, Kai Markus Schneider, Rohit Loomba
LINKED CONTENTThis article is linked to Schneider et al papers. To view these articles, visit https://doi.org/10.1111/apt.17958 and https://doi.org/10.1111/apt.17986
-
-
Magnetic resonance enterography findings 46 weeks after initiation of biological therapy predict long-term adverse outcomes in Crohn's disease Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-23 Agnès Fernández-Clotet, Ingrid Ordás, Maria Carme Masamunt, Berta Caballol, Sonia Rodríguez, Marta Gallego, Rebeca Barastegui, Anny Carolina Saavedra, Julián Panés, Elena Ricart, Jordi Rimola
-
Editorial: Are glucagon‐like peptide‐1 receptor agonists the functional cure for patients with metabolic dysfunction‐associated cirrhosis? Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-23 Elton Dajti, Susana G. Rodrigues
LINKED CONTENTThis article is linked to Elsaid et al paper. To view this article, visit https://doi.org/10.1111/apt.17925
-
Editorial: Novel insights into the prognostic relevance of high‐dose PPI treatment in patients with cirrhosis Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-23 Dominik Bettinger, Robert Thimme, Lukas Sturm
LINKED CONTENTThis article is linked to Yoon et al paper. To view this article, visit https://doi.org/10.1111/apt.17909
-
Editorial: Crystalising the burden of steatotic liver disease Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-23 Luis Calzadilla Bertot, Leon A. Adams
LINKED CONTENTThis article is linked to Schneider et al papers. To view these articles, visit https://doi.org/10.1111/apt.17958 and https://doi.org/10.1111/apt.17992
-
Randomised clinical trial: First‐line infliximab biosimilar is cost‐effective compared to conventional treatment in paediatric Crohn's disease Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-22 Stephanie A. Vuijk, Maria M. E. Jongsma, Britt M. Hoeven, Maarten A. Cozijnsen, Merel van Pieterson, Tim G. J. de Meij, Obbe F. Norbruis, Michael Groeneweg, Victorien M. Wolters, Herbert van Wering, Thalia Hummel, Janneke Stapelbroek, Cathelijne van der Feen, Patrick F. van Rheenen, Michiel P. van Wijk, Sarah Teklenburg, Dimitris Rizopoulos, Marten J. Poley, Johanna C. Escher, Lissy de Ridder
-
Editorial: Mortality in immune-mediated inflammatory diseases during early adulthood Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-21 Paul Henderson
Immune-mediated inflammatory diseases (IMIDs) have multifactorial aetiologies that share aberrant immune responses as the common final pathway. With the age-standardised incidence rate of IMIDs approaching 910/100,000 population at-risk in 2019, genetic–environmental interactions probably explain the variation in disease incidence across disease types and geographical regions.1, 2 Overall, most studies
-
Editorial: Foretelling the future—Emerging role of magnetic resonance enterography as a prognostic tool in Crohn's disease Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-21 Siri A. Urquhart, Joel G. Fletcher, David H. Bruining
This article is linked to Fernandez-Clotet et al paper. To view this article, visit https://doi.org/10.1111/apt.17968
-
Letter: Presence of progression or absence of response? Alternative trial designs for immunotherapy of advanced hepatocellular carcinoma Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-21 Enrico N. De Toni, Julia Mayerle, Bettina Oehrle, Max Seidensticker, Lorenza Rimassa, Alexander Philipp, Daniel Roessler, Najib Ben Khaled
This article is linked to Jost-Brinkmann et al papers. To view these articles, visit https://doi.org/10.1111/apt.17441 and https://doi.org/10.1111/apt.18008
-
Editorial: High qHBsAg—is it a good or bad signal? Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-21 Beom Kyung Kim
Quantitative hepatitis B surface antigen (qHBsAg) is one important biomarker intimately linked to the life cycle of the hepatitis B virus (HBV), allowing determination of treatment plans and prognoses.1 The total amount of intrahepatic cccDNA as well as its transcriptional activity really correlate with serum qHBsAg level.2 Hence, the higher qHBsAg had historically been thought to be a unfavourable
-
Editorial: Peering through the fog—New tools to assess neurocognitive symptoms in coeliac disease Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-21 Javier A. Villafuerte Gálvez, Daniel A. Leffler
Brain fog is increasingly recognised as a prevalent and burdensome syndrome that may occur in a wide range of conditions, including infection, inflammatory diseases, and chemotherapy. A single definition of brain fog remains elusive but often includes symptoms of cognitive dysfunction such as problems with concentration, information processing, memory, thinking, reasoning, and language comprehension
-
Editorial: Enriching our understanding of MASLD through representation of under-reported populations Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-21 Niharika Samala, Eduardo Vilar-Gomez
Metabolic dysfunction associated with steatotic liver disease (MASLD) has evolved into a leading cause of chronic liver disease.1, 2 Our current understanding of MASLD, is largely dictated by literature based on Western cohorts.3 Data regarding MASLD in people with HIV is sparse, with a notable gap from Sub-Saharan Africa.4 In the current manuscript, authors from Karolinska University (Sweden), Rakai
-
Letter: Risks of proton pump inhibitor treatment in cirrhotic patients Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-21 Jiamei Wang, Feng Wen, Jian Zhao
-
Letter: The enigma of angiotensin receptor blocker-associated enteropathy Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-21 Mustafa Mohamedrashed, Leya Nedumannil, Mayur Garg
We congratulate Schiepatti et al1 for an informative article that sheds light on the important clinical and pathological aspects of angiotensin receptor blocker (ARB)-associated enteropathy. Angiotensin receptor blocker-associated enteropathy presents a fascinating insight on the pathophysiology of the renin-angiotensin system (RAS) in the gastrointestinal tract (GIT). The crucial haemostatic roles
-
Editorial: Exploring the influence of diet on later-onset ulcerative colitis—Are eggs and spicy foods the key factors in Asia? Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-21 Shinji Okabayashi, Taku Kobayashi
This article is linked to Song et al papers. To view these articles, visit https://doi.org/10.1111/apt.17963 and https://doi.org/10.1111/apt.17999
-
Editorial: Redefining liver health—Personalised approach to assessment of serum ALT in clinical practice Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-21 Basile Njei, Joseph K. Lim
Alanine aminotransferase (ALT) is a crucial enzyme in diagnosing acute and chronic liver disease, reflecting liver health and function.1, 2 The upper limit of normal (ULN) for ALT levels is commonly applied uniformly across populations, disregarding variations due to metabolic health, gender and body mass index (BMI). To date, there is no universally accepted ULN value, although current US guidelines
-
Editorial: Can dietary gluten restriction improve hepatic steatosis? Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-21 Hariklia Kranidioti, Melanie Deutsch
Metabolic dysfunction-associated steatotic liver disease (MASLD) represents the modern global pandemia, affecting about 30% of the population worldwide.1, 2 The main driver of MASLD seems to be the classical metabolic syndrome associated with obesity, insulin resistance, type 2 diabetes mellitus, dyslipidaemia and hypertension, definitely together with genetics.3 Nowadays, MASLD represents a leading
-
Letter: Association of persistently high HBsAg levels during HBeAg-seropositive stage and hepatocellular carcinoma risk in chronic hepatitis B patients Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-21 Jian Wang, Yifan Pan, Ye Xiong, Chao Wu, Rui Huang
This article is linked to Lin et al papers. To view these articles, visit https://doi.org/10.1111/apt.17915 and https://doi.org/10.1111/apt.18009
-
Editorial: Are changes in quantitative biliary metrics the first sign of progression in primary sclerosing cholangitis? Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-21 John E. Eaton, Sudhakar K. Venkatesh
Large duct primary sclerosing cholangitis (PSC) is a rare chronic cholestatic liver disorder characterised by multifocal biliary strictures. A lack of validated surrogate markers that can be used in place of clinical endpoints in early-phase therapeutic trials makes drug development challenging.1 Historically, candidate surrogate endpoints for research and clinical practice have largely focused on
-
Diagnostic yield from symptomatic lower gastrointestinal endoscopy in the UK: A British Society of Gastroenterology analysis using data from the National Endoscopy Database Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-18 David Beaton, Linda Sharp, Liya Lu, Nigel Trudgill, Mo Thoufeeq, Brian Nicholson, Peter Rogers, James Docherty, Anna Jenkins, A. John Morris, Thomas Rösch, Matthew Rutter
-
Prospective evaluation of patients with non-cirrhotic portal hypertension: A single centre study Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-04-17 Maria Mironova, Harish Gopalakrishna, Gracia Maria Viana Rodriguez, Nehna Abdul Majeed, Asif A. Hitawala, Ivan J. Fuss, Jenna R. E. Bergerson, Alison J. Faust, Jacqueline M. Laurin, Jaha Norman-Wheeler, Shani Scott, Julian Hercun, Bernadette Redd, David E. Kleiner, Christopher Koh, Theo Heller